Literature DB >> 10536005

Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

N Morral1, W O'Neal, K Rice, M Leland, J Kaplan, P A Piedra, H Zhou, R J Parks, R Velji, E Aguilar-Córdova, S Wadsworth, F L Graham, S Kochanek, K D Carey, A L Beaudet.   

Abstract

The efficiency of first-generation adenoviral vectors as gene delivery tools is often limited by the short duration of transgene expression, which can be related to immune responses and to toxic effects of viral proteins. In addition, readministration is usually ineffective unless the animals are immunocompromised or a different adenovirus serotype is used. Recently, adenoviral vectors devoid of all viral coding sequences (helper-dependent or gutless vectors) have been developed to avoid expression of viral proteins. In mice, liver-directed gene transfer with AdSTK109, a helper-dependent adenoviral (Ad) vector containing the human alpha(1)-antitrypsin (hAAT) gene, resulted in sustained expression for longer than 10 months with negligible toxicity to the liver. In the present report, we have examined the duration of expression of AdSTK109 in the liver of baboons and compared it to first-generation vectors expressing hAAT. Transgene expression was limited to approximately 3-5 months with the first-generation vectors. In contrast, administration of AdSTK109 resulted in transgene expression for longer than a year in two of three baboons. We have also investigated the feasibility of circumventing the humoral response to the virus by sequential administration of vectors of different serotypes. We found that the ineffectiveness of readministration due to the humoral response to an Ad5 first-generation vector was overcome by use of an Ad2-based vector expressing hAAT. These data suggest that long-term expression of transgenes should be possible by combining the reduced immunogenicity and toxicity of helper-dependent vectors with sequential delivery of vectors of different serotypes.

Entities:  

Mesh:

Year:  1999        PMID: 10536005      PMCID: PMC23112          DOI: 10.1073/pnas.96.22.12816

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Authors:  H Zhou; W O'Neal; N Morral; A L Beaudet
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

2.  Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.

Authors:  D Armentano; J Zabner; C Sacks; C C Sookdeo; M P Smith; J A St George; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

Authors:  S Worgall; G Wolff; E Falck-Pedersen; R G Crystal
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

4.  Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ.

Authors:  G Wolff; S Worgall; N van Rooijen; W R Song; B G Harvey; R G Crystal
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Construction of adenovirus vectors through Cre-lox recombination.

Authors:  S Hardy; M Kitamura; T Harris-Stansil; Y Dai; M L Phipps
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes.

Authors:  S E Haecker; H H Stedman; R J Balice-Gordon; D B Smith; J P Greelish; M A Mitchell; A Wells; H L Sweeney; J M Wilson
Journal:  Hum Gene Ther       Date:  1996-10-01       Impact factor: 5.695

8.  Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver.

Authors:  Y Yang; K Greenough; J M Wilson
Journal:  Gene Ther       Date:  1996-05       Impact factor: 5.250

9.  Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.

Authors:  C A Mack; W R Song; H Carpenter; T J Wickham; I Kovesdi; B G Harvey; C J Magovern; O W Isom; T Rosengart; E Falck-Pedersen; N R Hackett; R G Crystal; A Mastrangeli
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

10.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

View more
  119 in total

1.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.

Authors:  Philip Ng; Carole Evelegh; Derek Cummings; Frank L Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector.

Authors:  Shuji Kubo; Kohnosuke Mitani
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

6.  Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain.

Authors:  Mihail Y Mastakov; Kristin Baer; C Wymond Symes; Claudia B Leichtlein; Robert M Kotin; Matthew J During
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors.

Authors:  Florian Kreppel; Stefan Kochanek
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  E1A and E1B proteins inhibit inflammation induced by adenovirus.

Authors:  Jerome Schaack; Michael L Bennett; Jeff D Colbert; Andres Vazquez Torres; Gerald H Clayton; David Ornelles; John Moorhead
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

10.  Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin.

Authors:  Ruben Hernandez-Alcoceba; Pedro Berraondo
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.